Notice of Proposed Sale · 144
Ionis Pharmaceuticals, Inc.
IONSNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- IONIS PHARMACEUTICALS INC
- Issuer CIK
- 0000874015
- SEC file number
- 000-19125
- Phone
- 7609319200
- Person for whose account securities are to be sold
- BENNETT C FRANK
- Relationships to issuer
- Officer
- Street
- 2855 GAZELLE COURT
- City
- CARLSBAD
- State / country code
- CA
- Postal code
- 92010
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 67,386 | 5,724,724.00 | 165,262,556 | 07/07/2026 | Nasdaq | Stifel Nicolaus & Company Inc |
Broker / market maker — proposed row 1, entry 1
- Name
- Stifel Nicolaus & Company Inc
- Street
- 501 N Broadway
- City
- St. Louis
- State / country code
- MO
- Postal code
- 63102
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 01/15/2020 | Owned Shares | Issuer | 20,536 | N | 01/15/2020 | Equity Compensation |
| Common Stock | 01/04/2021 | Stock Option Exercise | Issuer | 46,850 | N | 07/07/2026 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
Owned Shares are from various restricted stock unit vest events from 1/15/2020 to 1/29/2026
Notice signature
- Notice date
- 07/07/2026
- Signed
- /s/ James Weimer, as a duly authorized representative of STIFEL, as attorney-in-fact for Frank Bennett
- Plan adoption dates
- 03/31/2026
Company context
For more than three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.